Epratuzumab News and Research

RSS
Epratuzumab is a humanized monoclonal antibody that targets CD22 antigen, found on the surface of B-lymphocytes, a type of white blood cell. Epratuzumab is being evaluated in patients with Sjogren's syndrome and is also Immunomedics' lead product candidate in two pivotal Phase III trials for the treatment of patients with moderate and severe systemic lupus erythematosus (SLE). The FDA granted a Fast Track designation to the clinical development program for epratuzumab for the treatment of patients with SLE. Epratuzumab has also demonstrated good safety, tolerability, and clinical effect in more than 340 patients with non-Hodgkin's lymphoma, resulting in reports published in The Journal of Clinical Oncology and Clinical Cancer Research.
Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

Pfizer halts Phase 3 open-label, two-arm study of lymphoma drug

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

New data from Pfizer's hematology portfolio to be presented at 53rd ASH annual meeting

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Immunomedics reports net loss of $3.4M in total revenues for second quarter 2011

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Immunomedics reports encouraging results from Y-90-labeled clivatuzumab tetraxetan study in pancreatic cancer

Immunomedics announces additional claim for RS7 antibodies patent family

Immunomedics announces additional claim for RS7 antibodies patent family

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Immunomedics reports CD22 antibody produced significant anti-tumor response

Immunomedics reports CD22 antibody produced significant anti-tumor response

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Consolidation treatment with Y-90 epratuzumab after R-CHOP improves remission in DLBCL lymphoma

Epratuzumab-rituximab combination therapy effective against previously untreated follicular lymphoma

Epratuzumab-rituximab combination therapy effective against previously untreated follicular lymphoma

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

Immunomedics reports results of milatuzumab-based combination treatments for NHL patients

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Pfizer to present data on hematology portfolio at ASH Annual Meeting

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

Epratuzumab reduces SLE disease activity in phase IIB EMBLEM study

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics receives additional patent claims for antibody therapy

Immunomedics receives additional patent claims for antibody therapy

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Immunomedics 2010 fourth quarter revenue decreases to $0.7 million

Immunomedics, GE Healthcare collaborate to evaluate peptide labeling technologies

Immunomedics, GE Healthcare collaborate to evaluate peptide labeling technologies

Immunomedics receives additional patent for CD74 target

Immunomedics receives additional patent for CD74 target

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE

Phase IIb EMBLEM study demonstrates clinical efficacy of epratuzumab in patients with SLE